Jasper Therapeutics, Inc. is a biotechnology company based in Redwood City, CA, specializing in the development of targeted therapies for chronic diseases. Their mission is to provide safer and potentially curative treatments for patients in need by focusing on mast cells and stem cells. With a team of experienced industry professionals and collaborations with leading academic institutions, Jasper Therapeutics aims to develop innovative therapies for diseases related to mast and stem cells, as well as safer conditioning methods for monogenetic diseases. One of their key products is briquilimab, a targeted anti c-Kit monoclonal antibody designed to deplete mast cells and diseased stem cells. This antibody has the potential to enable safer and more effective curative hematopoietic stem cell transplants and stem cell gene therapies. Jasper Therapeutics is currently studying briquilimab for various diseases, including chronic urticaria, lower to intermediate risk myelodysplastic syndromes (MDS), and as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA), and severe combined immunodeficiency (SCID).
Generated from the website
